CONCENTRATIONS OF RISK

12 Months Ended

Apr. 30, 2026

NOTE 10 — CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risk:

(a)

Cash

The Company maintains cash with banks in the United States of America (“USA”). Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In the United States, the standard insurance amount is $250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”).

Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash. As of April 30, 2026 and 2025, $627,192 and $301,267 of the Company’s cash held by financial institutions were uninsured, respectively.

(a)	Major customers

For the years ended April 30, 2026 and 2025, the individual customers who accounted for 10% of the Company’s revenue and its outstanding accounts receivable balance at period-end date:

Schedule of concentrations risk
	For the Year ended April 30, 2026					As of April 30, 2026
	Revenues		Percentage of revenues			Accounts receivable
Customer A	$	345,578		11%		$	188,801
Customer D		724,484		24%			85,875
Customer E		587,010		19%			146,960
TOTAL	$	1,657,072		54%	Total	$	421,636

	For the Year ended April 30, 2025					As of April 30, 2025
	Revenues		Percentage of revenues			Accounts receivable
Customer A	$	1,072,230		40%		$	501,512
Customer B		972,168		37%			494,500
Customer C		374,880		14%			238,208
TOTAL	$	2,419,278		91%	Total	$	1,234,220

(b)	Major vendors

For the years ended April 30, 2026 and 2025, the following vendor accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balance at period-end date:

Schedule of concentrations risk
	For the Year ended April 30, 2026				As of April 30, 2026
Vendor	Purchases		Percentage of purchases		Accounts payable
Vendor A	$	891,350		41%	$	72,828
Vendor B		736,000		34%		–
Vendor C		317,800		15%		110,060
Vendor D		231,014		11%		–
TOTAL	$	2,176,164		100%	$	182,888

For the Year ended
April 30, 2025

As of April 30, 2025

Vendor

Purchases

Percentage
of purchases

Accounts
payable

Vendor A

966,422

86%

–

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

+ Details

VitaNova Life Sciences Corp 10-K